Effectiveness of Non-Animal Chondroitin Sulfate Supplementation in the Treatment of Moderate Knee Osteoarthritis in a Group of Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Rondanelli, Mariangela; Braschi, Valentina; Gasparri, Clara; Nichetti, Mara; Faliva, Milena Anna; Peroni, Gabriella; Naso, Maurizio; Iannello, Giancarlo; Spadaccini, Daniele; Miraglia, Niccolò; Putignano, Pietro; Alalwan, Tariq A.; Perna, Simone

doi:10.3390/nu11092027

Cited by 16 publications

(17 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A major solution to the limitations associated with the current state-of-art CS production is production using animal-free methods [21][22][23] . Chemical, chemoenzymatic, microbial, and mammalian cell-culture based CS production systems are being developed worldwide 21 .…”

mentioning

confidence: 99%

Complete biosynthesis of a sulfated chondroitin in Escherichia coli

et al. 2021

View full text Add to dashboard Cite

Sulfated glycosaminoglycans (GAGs) are a class of important biologics that are currently manufactured by extraction from animal tissues. Although such methods are unsustainable and prone to contamination, animal-free production methods have not emerged as competitive alternatives due to complexities in scale-up, requirement for multiple stages and cost of co-factors and purification. Here, we demonstrate the development of single microbial cell factories capable of complete, one-step biosynthesis of chondroitin sulfate (CS), a type of GAG. We engineer E. coli to produce all three required components for CS production–chondroitin, sulfate donor and sulfotransferase. In this way, we achieve intracellular CS production of ~27 μg/g dry-cell-weight with about 96% of the disaccharides sulfated. We further explore four different factors that can affect the sulfation levels of this microbial product. Overall, this is a demonstration of simple, one-step microbial production of a sulfated GAG and marks an important step in the animal-free production of these molecules.

show abstract

mentioning

confidence: 99%

Complete biosynthesis of a sulfated chondroitin in Escherichia coli

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Boswellin: (β‐boswellic acids 87.3 mg × 2/day) (n = 22) 2. Placebo (n = 20) – RCT 120 days WOMAC, 6 MW, Pain (VAS), QOL(European Quality of life‐5 Dimension, JSW Rondanelli 2019 57 Italy Knee OA (mild to moderate according to KLS) Aged ≥ 55 years BMI: 25–30 kg/m 2 VAS: 40–70 mm 1. CS (600 × 1/mg) (n = 30) 2.…”

Section: Resultsmentioning

confidence: 99%

“…There was no significant difference between the ParActin groups and the placebo in the total number of adverse events Majeed 2019 56 12% (n = 6) Adverse events have been supervised. No safety problems were recognized Rondanelli 2019 57 0 Adverse events have been supervised. No safety problems were recognized ART Artemisia annua extract, ASU Avocado soybean unsaponifiable, DBE Deer bone extract, GC Glucosamine hydrochloride + chondroitin sulfate, GS Glucosamine sulphate, MSM Methylsulfonylmethane, PCP Collagen peptides isolated from pork skin, UC-II Undenatured collagen type II.…”

Section: Resultsmentioning

confidence: 99%

“…Investigations in animal models have suggested that dietary supplements of CS prevent articular cartilage depreciation 66 . This protecting consequence is related to the anti-inflammatory activities of CS by increasing the synthesis of hyaluronic acid and proteoglycans, and decreasing the production of proteolytic enzymes and nitric oxide 57 . Deer horn extract has been considered as a noteworthy health restorative in traditional medicine amongst several Asian countries 67 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nutraceutical supplements in management of pain and disability in osteoarthritis: a systematic review and meta-analysis of randomized clinical trials

Aghamohammadi

Dolatkhah

Bakhtiari

et al. 2020

Sci Rep

View full text Add to dashboard Cite

This study designed to evaluate the effect of nutraceutical supplementation on pain intensity and physical function in patients with knee/hip OA. The MEDLINE, Web of Science, Cochrane Library, Scopus, EMBASE, Google Scholar, Science direct, and ProQuest in addition to SID, Magiran, and Iranmedex were searched up to March 2020. Records (n = 465) were screened via the PICOS criteria: participants were patients with hip or knee OA; intervention was different nutritional supplements; comparator was any comparator; the outcome was pain intensity (Visual analogue scale [VAS]) and physical function (Western Ontario and McMaster Universities Arthritis [WOMAC] index); study type was randomized controlled trials. The random effects model was used to pool the calculated effect sizes. The standardized mean difference (SMD) of the outcome changes was considered as the effect size. The random effects model was used to combine the effect sizes. Heterogeneity between studies was assessed by Cochran's (Q) and I2 statistics. A total of 42 RCTs were involved in the meta-analysis. Nutritional supplementation were found to improve total WOMAC index (SMD = − 0.23, 95% CI − 0.37 to − 0.08), WOMAC pain (SMD = − 0.36, 95% CI − 0.62 to − 0.10) and WOMAC stiffness (SMD = − 0.47, 95% CI − 0.71 to − 0.23) subscales and VAS (SMD = − 0.79, 95% CI − 1.05 to − 0.05). Results of subgroup analysis according to the supplementation duration showed that the pooled effect size in studies with < 10 months, 10–20 months and > 20 months supplementation duration were 0.05, 0.27, and 0.36, respectively for WOMAC total score, 0.14, 0.55 and 0.05, respectively for WOAMC pain subscale, 0.59, 0.47 and 0.41, respectively for WOMAC stiffness subscale, 0.05, 0.57 and 0.53, respectively for WOMAC physical function subscale and 0.65, 0.99 and 0.12, respectively for VAS pain. The result suggested that nutraceutical supplementation of patients with knee/hip OA may lead to an improvement in pain intensity and physical function.

show abstract

“…Blood is easily withdrawn and mediates many of the immunologic pathways. The most widely studied OA biomarkers through blood test are inflammatory cytokines like interlukin-1β, tumor necrosis factor-α, and C-reactive protein, which are highly associated with symptomatic and radiographic progression of OA (18,19). Their levels may provide the possibility to dynamically monitor the severity and progression of OA.…”

Section: Body Fluid: Readily Accessible Molecular Pool For Oa Diagnosismentioning

confidence: 99%